Congenital cystic adenomatoid malformations of the lung: an epithelial transcriptomic approach.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
04 Feb 2020
Historique:
received: 05 11 2019
accepted: 27 01 2020
entrez: 6 2 2020
pubmed: 6 2 2020
medline: 24 11 2020
Statut: epublish

Résumé

The pathophysiology of congenital cystic adenomatoid malformations (CCAM) of the lung remains poorly understood. This study aimed to identify more precisely the molecular mechanisms limited to a compartment of lung tissue, through a transcriptomic analysis of the epithelium of macrocystic forms. Tissue fragments displaying CCAM were obtained during planned surgical resections. Epithelial mRNA was obtained from cystic and normal areas after laser capture microdissection (LCM). Transcriptomic analyses were performed and the results were confirmed by RT-PCR and immunohistochemistry in independent samples. After controlling for RNA quality, we analysed the transcriptomes of six cystic areas and five control areas. In total, 393 transcripts were differentially expressed in the epithelium, between CCAM and control areas. The most highly redundant genes involved in biological functions and signalling pathways differentially expressed between CCAM and control epithelium included TGFB2, TGFBR1, and MAP 2 K1. These genes were considered particularly relevant as they have been implicated in branching morphogenesis. RT-qPCR analysis confirmed in independent samples that TGFBR1 was more strongly expressed in CCAM than in control tissues (p < 0.03). Immunohistochemistry analysis showed TGFBR1 (p = 0.0007) and TGFB2 (p < 0.02) levels to be significantly higher in the epithelium of CCAM than in that of control tissues. This compartmentalised transcriptomic analysis of the epithelium of macrocystic lung malformations identified a dysregulation of TGFB signalling at the mRNA and protein levels, suggesting a possible role of this pathway in CCAM pathogenesis. ClinicalTrials.gov Identifier: NCT01732185.

Sections du résumé

BACKGROUND BACKGROUND
The pathophysiology of congenital cystic adenomatoid malformations (CCAM) of the lung remains poorly understood.
AIM OBJECTIVE
This study aimed to identify more precisely the molecular mechanisms limited to a compartment of lung tissue, through a transcriptomic analysis of the epithelium of macrocystic forms.
METHODS METHODS
Tissue fragments displaying CCAM were obtained during planned surgical resections. Epithelial mRNA was obtained from cystic and normal areas after laser capture microdissection (LCM). Transcriptomic analyses were performed and the results were confirmed by RT-PCR and immunohistochemistry in independent samples.
RESULTS RESULTS
After controlling for RNA quality, we analysed the transcriptomes of six cystic areas and five control areas. In total, 393 transcripts were differentially expressed in the epithelium, between CCAM and control areas. The most highly redundant genes involved in biological functions and signalling pathways differentially expressed between CCAM and control epithelium included TGFB2, TGFBR1, and MAP 2 K1. These genes were considered particularly relevant as they have been implicated in branching morphogenesis. RT-qPCR analysis confirmed in independent samples that TGFBR1 was more strongly expressed in CCAM than in control tissues (p < 0.03). Immunohistochemistry analysis showed TGFBR1 (p = 0.0007) and TGFB2 (p < 0.02) levels to be significantly higher in the epithelium of CCAM than in that of control tissues.
CONCLUSIONS CONCLUSIONS
This compartmentalised transcriptomic analysis of the epithelium of macrocystic lung malformations identified a dysregulation of TGFB signalling at the mRNA and protein levels, suggesting a possible role of this pathway in CCAM pathogenesis.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov Identifier: NCT01732185.

Identifiants

pubmed: 32019538
doi: 10.1186/s12931-020-1306-5
pii: 10.1186/s12931-020-1306-5
pmc: PMC7001206
doi:

Substances chimiques

Early Growth Response Transcription Factors 0
KLF10 protein, human 0
Kruppel-Like Transcription Factors 0
RNA, Messenger 0

Banques de données

ClinicalTrials.gov
['NCT01732185']

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43

Subventions

Organisme : Assistance Publique - Hôpitaux de Paris
ID : PHRC 2012-A00538-35

Références

Development. 2014 Jan;141(1):91-100
pubmed: 24284203
Dev Dyn. 2017 Jan;246(1):72-82
pubmed: 27748998
Scientifica (Cairo). 2014;2014:538379
pubmed: 25298902
Zoolog Sci. 2014 May;31(5):267-73
pubmed: 24832898
Dev Biol. 1996 Nov 25;180(1):242-57
pubmed: 8948588
Am J Respir Crit Care Med. 2018 May 15;197(10):1328-1339
pubmed: 29328793
Methods Mol Biol. 2019;1882:253-259
pubmed: 30378061
Dev Cell. 2010 Jan 19;18(1):8-23
pubmed: 20152174
Development. 1997 Jul;124(13):2659-70
pubmed: 9217007
Am J Physiol Lung Cell Mol Physiol. 2010 Oct;299(4):L455-71
pubmed: 20622121
FASEB J. 2017 Aug;31(8):3298-3308
pubmed: 28446590
Paediatr Respir Rev. 2016 Jun;19:62-8
pubmed: 26907828
Development. 2010 Mar;137(5):825-33
pubmed: 20147383
Ultrastruct Pathol. 1982 Jul-Sep;3(3):217-28
pubmed: 6293133
Nature. 2003 Oct 9;425(6958):577-84
pubmed: 14534577
Mech Dev. 2001 Nov;109(1):13-26
pubmed: 11677049
J Cell Biol. 2007 Jul 30;178(3):437-51
pubmed: 17646396
Dev Dyn. 2012 May;241(5):911-23
pubmed: 22411169
Am J Physiol Lung Cell Mol Physiol. 2015 Oct 15;309(8):L751-5
pubmed: 26342090
Am J Physiol Lung Cell Mol Physiol. 2016 Sep 1;311(3):L529-37
pubmed: 27422998
Lab Invest. 2019 Sep;99(9):1363-1375
pubmed: 31028279
Int J Mol Sci. 2018 Aug 20;19(8):null
pubmed: 30127261
Front Genet. 2018 Sep 25;9:418
pubmed: 30319693
Orphanet J Rare Dis. 2013 Sep 03;8:130
pubmed: 24004862
Am J Respir Cell Mol Biol. 2016 May;54(5):647-55
pubmed: 26796672

Auteurs

Guillaume Lezmi (G)

Service de Pneumologie et d'Allergologie Pédiatriques, AP-HP, Hôpital Universitaire Necker-Enfants Malades, 75743 Cedex 15, Paris, France.
INSERM, U955, Institut Mondor de Recherche Biomedicale (IMRB), Equipe 4, 94000, Créteil, France.
Paris Descartes University, Paris, France.

Shamila Vibhushan (S)

INSERM, U955, Institut Mondor de Recherche Biomedicale (IMRB), Equipe 4, 94000, Créteil, France.

Claudia Bevilaqua (C)

Institut National de la Recherche Agronomique (INRA), AgroParisTech, Université Paris-Saclay, Jouy en Josas, France.

Nicolas Crapart (N)

Institut National de la Recherche Agronomique (INRA), AgroParisTech, Université Paris-Saclay, Jouy en Josas, France.

Nicolas Cagnard (N)

Inserm UMR1163, Imagine Institute, Genomics Core Facility, Paris, France.

Naziha Khen-Dunlop (N)

Paris Descartes University, Paris, France.
Service de Chirurgie Pédiatrique, AP-HP, Hôpital Universitaire Necker-Enfants Malades, 75743 Cedex 15, Paris, France.

Christine Boyle-Freyssaut (C)

Inserm UMR1163, Imagine Institute, Genomics Core Facility, Paris, France.

Alice Hadchouel (A)

Service de Pneumologie et d'Allergologie Pédiatriques, AP-HP, Hôpital Universitaire Necker-Enfants Malades, 75743 Cedex 15, Paris, France.
INSERM, U955, Institut Mondor de Recherche Biomedicale (IMRB), Equipe 4, 94000, Créteil, France.
Paris Descartes University, Paris, France.

Christophe Delacourt (C)

Service de Pneumologie et d'Allergologie Pédiatriques, AP-HP, Hôpital Universitaire Necker-Enfants Malades, 75743 Cedex 15, Paris, France. christophe.delacourt@aphp.fr.
INSERM, U955, Institut Mondor de Recherche Biomedicale (IMRB), Equipe 4, 94000, Créteil, France. christophe.delacourt@aphp.fr.
Paris Descartes University, Paris, France. christophe.delacourt@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH